Surprise! Roche Says It Will Not Pursue Herceptin Patents In India
This article was originally published in PharmAsia News
Executive Summary
In a surprising move, Roche has decided to give up its patents for Herceptin in India, leaving the way open for generic drug makers eyeing the booming market. But do any local firms have the capabilities to develop and manufacture a biosimilar of trastuzumab?